研究者
J-GLOBAL ID:201301080088849080
更新日: 2020年08月25日
木村 恵
キムラ メグミ | Kimura Megumi
論文 (16件):
Goki Suda, Jun Ito, Atsushi Nagasaka, Yoshiya Yamamoto, Ken Furuya, Munenori Okamoto, Katsumi Terashita, Tomoe Kobayashi, Izumi Tsunematsu, Junichi Yoshida, et al. Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. Hepatology research : the official journal of the Japan Society of Hepatology. 2018. 48. 3. E146-E154
Naoki Kawagishi, Goki Suda, Masahiro Onozawa, Megumi Kimura, Osamu Maehara, Jun Ito, Masato Nakai, Takuya Sho, Mitsuteru Natsuizaka, Kenichi Morikawa, et al. Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. JOURNAL OF HEPATOLOGY. 2017. 67. 5. 1106-1108
Osamu Maehara, Goki Suda, Mitsuteru Natsuizaka, Shunsuke Ohnishi, Yoshito Komatsu, Fumiyuki Sato, Masato Nakai, Takuya Sho, Kenichi Morikawa, Koji Ogawa, et al. Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. CARCINOGENESIS. 2017. 38. 11. 1073-1083
Goki Suda, Atsushi Nagasaka, Yoshiya Yamamoto, Ken Furuya, Kenichi Kumagai, Mineo Kudo, Katsumi Terashita, Tomoe Kobayashi, Izumi Tsunematsu, Junichi Yoshida, et al. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. HEPATOLOGY RESEARCH. 2017. 47. 11. 1127-1136
Goki Suda, Koji Ogawa, Yoshiya Yamamoto, Masaki Katagiri, Ken Furuya, Kenichi Kumagai, Jun Konno, Megumi Kimura, Naoki Kawagishi, Masatsugu Ohara, et al. Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. JOURNAL OF GASTROENTEROLOGY. 2017. 52. 10. 1122-1129
もっと見る
学位 (1件):
薬学博士 (北海道大学)
経歴 (2件):
2012/12 - 現在 北海道大学 医学(系)研究科(研究院) 学術研究員
2011/04 - 2012/12 北海道大学 医学(系)研究科(研究院) 助教
※ J-GLOBALの研究者情報は、
researchmap
の登録情報に基づき表示しています。 登録・更新については、
こちら
をご覧ください。
前のページに戻る
TOP
BOTTOM